Adenosine Pathway Inhibitors In Kidney Cancer
Abhishek Tripathi, M.D. Assistant Professor Of Medicine In The Section Of Hematology/Oncology At Oklahoma Stephenson Cancer Center Discusses Adenosine Pathway Inhibitors In Kidney Cancer. At the Seven...
Author: kidneycancer
Added: 01/28/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 28, 2019 Category: Cancer & Oncology Source Type: podcasts
More Trials & Drugs Coming In 2019
Lisa X. Lee, M.D. Hematology/Oncology Specialist At University of California, Irvine Discusses, More Trials & Drugs Coming In 2019. At MOASC on Jan 19, 2019.
Author: moasc
Added: 01/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 28, 2019 Category: Cancer & Oncology Source Type: podcasts
How MAIA & FORTE Trials Effect Clinicians
Lisa X. Lee, M.D. Hematology/Oncology Specialist At University of California, Irvine Discusses, How MAIA & FORTE Trials Effect Clinicians. At MOASC on Jan 19, 2019.
Author: moasc
Added: 01/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 28, 2019 Category: Cancer & Oncology Source Type: podcasts
Highlights Of MAIA, FORTE & Tourmaline MM-3 Trials
Lisa X. Lee, M.D. Hematology/Oncology Specialist At University of California, Irvine Discusses, Highlights Of MAIA, FORTE & Tourmaline MM-3 Trials. At MOASC on Jan 19, 2019.
Author: moasc
Added: 01/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 28, 2019 Category: Cancer & Oncology Source Type: podcasts
Data On The ALLIANCE Trial
Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses Data On The ALLIANCE Trial. At MOASC on Jan 19, 2019.
Author: moasc
Added: 01/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 28, 2019 Category: Cancer & Oncology Source Type: podcasts
ALLIANCE Trial & Low MRD
Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses ALLIANCE Trial & Low MRD. At MOASC on Jan 19, 2019.
Author: moasc
Added: 01/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 28, 2019 Category: Cancer & Oncology Source Type: podcasts
ALLIANCE Trial & Its Effect On Clinicians
Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses ALLIANCE Trial & Its Effect On Clinicians. At MOASC on Jan 19, 2019.
Author: moasc
Added: 01/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 28, 2019 Category: Cancer & Oncology Source Type: podcasts
How The MAIA Trial Will Effect Clinicians
Tianyi Tang, M.D. Hematology/Oncology Fellow At University of California, Irvine Discusses How The MAIA Trial Will Effect Clinicians . At MOASC on Jan 19, 2019.
Author: moasc
Added: 01/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 28, 2019 Category: Cancer & Oncology Source Type: podcasts
Highlights Of The MAIA Trial
Tianyi Tang, M.D. Hematology/Oncology Fellow At University of California, Irvine Discusses Highlights Of The MAIA Trial. At MOASC on Jan 19, 2019.
Author: moasc
Added: 01/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 28, 2019 Category: Cancer & Oncology Source Type: podcasts
Three New Drugs Approved For AML
Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Three New Drugs Approved For AML. At MOASC on Jan 19, 2019.
Author: moasc
Added: 01/25/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2019 Category: Cancer & Oncology Source Type: podcasts
Dosing Regarding Venetoclax
Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Dosing Regarding Venetoclax. At MOASC on Jan 19, 2019.
Author: moasc
Added: 01/25/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2019 Category: Cancer & Oncology Source Type: podcasts
Can Glasdegib Be Used As A Single Agent
Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Can Glasdegib Be Used As A Single Agent. At MOASC on Jan 19, 2019.
Author: moasc
Added: 01/25/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 25, 2019 Category: Cancer & Oncology Source Type: podcasts
Can A Rituximab Biosimilar Replace Rituximab
Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses Can A Rituximab Biosimilar Replace Rituximab. At The 60th ASH Ann...
Author: obr
Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts
GRIFFIN Trial Safety & Efficacy
Peter Vorhees, MD, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses GRIFFIN Trial Safety & Efficacy. At The 60th...
Author: obr
Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts
CAR-T Therapy FDA Approvals
Elizabeth Budde, MD, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses CAR-T Therapy FDA Approvals. At The 60th ASH Annual Meeting on De...
Author: obr
Added: 01/15/2019 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2019 Category: Cancer & Oncology Source Type: podcasts
